PEDIATRICS Vol. 88 No. 5 November 1991, pp. 966
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

STILL THERAPEUTIC ORPHANS!

Historically, children have not shared in therapeutic advances to the same extent adults have. A recent survey of the 1990 Physicians Desk Reference (PDR) by the AAP Committee on Drugs reveals that the labeling for 75% of medications listed in the 1990 PDR contains disclaimers or precautions against use in children of all ages. Advisories against use by infants and toddlers is contained in the labeling of 91% of medications.

A recent review of new molecular entities, which represent the most innovative new medications, approved by the Food and Drug Administration from 1984 through 1989 reveals that 80% of these medications currently are not approved for use in children.